BICYCLE THERAPEUTICS PLCBCYCEarnings & Financial Report
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.
Revenue
$19.5M
Gross Profit
N/A
Operating Profit
$-31.7M
Net Profit
$-26.6M
Gross Margin
N/A
Operating Margin
-162.4%
Net Margin
-136.0%
YoY Growth
298.9%
EPS
$-0.62
BICYCLE THERAPEUTICS PLC Q1 FY2024 Financial Summary
BICYCLE THERAPEUTICS PLC reported revenue of $19.5M (up 298.9% YoY) for Q1 FY2024, with a net profit of $-26.6M (up 32.0% YoY) (-136.0% margin).
Key Financial Metrics
| Total Revenue | $19.5M |
|---|---|
| Net Profit | $-26.6M |
| Gross Margin | N/A |
| Operating Margin | -162.4% |
| Report Period | Q1 FY2024 |
Revenue Breakdown
BICYCLE THERAPEUTICS PLC Q1 FY2024 revenue of $19.5M breaks down across 4 segments, led by Genentech at $11.6M (59.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Genentech | $11.6M | 59.5% |
| Ionis Collaboration Agreement | $5.9M | 30.0% |
| Novartis Collaboration Agreement | $1.2M | 6.4% |
| Other | $818.0K | 4.2% |
BICYCLE THERAPEUTICS PLC Annual Revenue by Year
BICYCLE THERAPEUTICS PLC annual revenue history includes year-by-year totals (for example, 2025 revenue was $72.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $72.6M |
| 2024 | $35.3M |
| 2023 | $27.0M |
| 2022 | $14.5M |
BICYCLE THERAPEUTICS PLC Quarterly Revenue & Net Profit History
BICYCLE THERAPEUTICS PLC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $48.0M | +1193.3% | $-20.2M | -42.0% |
| Q3 FY2025 | $11.7M | +338.5% | $-59.1M | -503.7% |
| Q2 FY2025 | $2.9M | -68.8% | $-79.0M | -2703.8% |
| Q1 FY2025 | $10.0M | -48.9% | $-60.8M | -608.9% |
| Q4 FY2024 | $3.7M | -30.4% | N/A | N/A |
| Q3 FY2024 | $2.7M | -50.0% | $-50.8M | -1898.4% |
| Q2 FY2024 | $9.4M | -17.9% | $-39.8M | -425.3% |
| Q1 FY2024 | $19.5M | +298.9% | $-26.6M | -136.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $9.4M | $2.7M | $3.7M | $10.0M | $2.9M | $11.7M | $48.0M |
| YoY Growth | 298.9% | -17.9% | -50.0% | -30.4% | -48.9% | -68.8% | 338.5% | 1193.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $547.1M | $1.06B | $996.7M | $956.9M | $883.9M | $832.2M | $764.0M | $717.6M |
| Liabilities | $191.1M | $183.5M | $165.7M | $163.8M | $143.6M | $163.3M | $145.5M | $107.6M |
| Equity | $356.0M | $873.8M | $831.0M | $793.1M | $740.3M | $668.9M | $618.5M | $610.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-70.9M | $-44.6M | $-39.8M | $-164.7M | $-86.4M | $-72.8M | $-71.2M | $-19.3M |